Among 685 patients diagnosed and treated at the centre of Hematology and blood transfusion of HCM city, from 6/95 to 6/98 has included as ALL (258 cases) and AML (376 cases). However, only 175 of them have followed a full-term treatment applied at the centre (fralle protocol for ALL children. BGMT for ALL adults and 3-7 for AML). The percentage of ALL patients achieving CR was 88.33% and of AML ones was 78.43%. The average survival time of ALL patients was 24 months and 12 months for AML. The current protocol applied at the Center had relatively good results especially in the ALL children.
Leukemia ; therapy ; therapeutics

Treatment of acute lymphoid leukemia at the Center of Hematology and Blood Transfusion of Ho Chi Minh city. A ten-year survey 1990-2000. Among 1,317 patients diagnosed as ALL during the past ten years, 197 of them have followed a full-term treatment according to either BGMT protocol, for adults, or FRALLE, for children. The percentage of patients achieving CR is comparable to foreign authors, but the DFS of our patients is clearly lower: 45% (5 years) and the Medicum Remission Duration (MRD) is 48 months for children and DFS = 35% (5 years) MRD = 9 months for adults. Risk factors influence significantly on the issue of therapy; children have better prognosis than adults; patients who have myelois cell marker(s) get poorer result than those who have not. Relapse occurs mostly in the bone marrow, rather than neuro-menigeal and gonadic sites.
Leukemia, Lymphocytic, Acute ; therapy ; therapeutics

Between 3/1990 and 5/2000, 249 patients with AML were treated at the Ho Chi Minh center for hematology and blood transfusion. The results were the following: complete remission achieved in 63% patients treated with 7&3 protocol, 77% with 7&3&5 protocol, 8% with Ara-C+ Purinethol protocol and 2% with Ara-C or Purinethol alone protocol. Overall survival at 12 months of patients treated with 7& 3, 7&3&5, and Ara-C+ Purinethol protocol were 32%, 69% and 16%, respectively. Conclusion, induction chemotherapy with 7&3 and 7&3&5 protocols achieved better results in patients with AML.
Leukemia, Myelocytic, Acute ; drug therapy

Induction chemotherapy of 7-3-5 protocol (cytarabine, daunorubicin, etoposide) in acute myeloid leukemia. Between October 1998 and October 1999, 10 patients with AML (4M, 6F, median age 31) were treated with induction chemotherapy of 7-3-5 protocol at the blood transfusion and hematology center, HCM city. A complete remission was achieved in 9 of 10 patients. 1 patient died from transfusion- associated graft- versus- host disease. The median time to recover ANC> 05x 109/1 and platelets> 20x109/1 were 16 days. Oral mucositis was mild in 2 patients. 7-3-5 protocol may be more effective than 7-3 protocol in response rate and prolonged remission but toxicity was similar.
Leukemia, Myelocytic, Acute ; therapy ; therapeutics

From 3/1999 to 11/2001, 27 patients (age 6-48, 15 males and 12 females) with AML (21 denovo, 4 relape, 2 biphenotype) were treated with induction chemotherapy of 7-3-5 protocol at the blood transfusion and hematology center HCM city. 81.5% (22/27) patients were complete remission but one died on 32th due to fungal infection of the lung, 7.4% patients had no remission, 11.1% patients induction deaths due to infection and GVHD after transfusion. Neutrophil recovery > 0.5x 109/l by allocated treatment is 17 days and platelet > 100x 109/l is 18 days. CR of 7-3-5 protocol is higher than 7-3 protocol. Toxicity of drug is the same.
Leukemia, Erythroblastic, Acute ; therapy ; therapeutics

Humans ; Leukemia, Myelomonocytic, Juvenile/therapy*

46 patients with acute promyelocytic leukemia (APL) have been treated by ATRA (all trans retinoic acid). The result showed that 33 patients (72%) were complete remission. Two patients in relapse have been treated by ATRA plus As2O3 (arsenic trioside). The both patients were complete remission. The results of the present study showed that ATRA is standard drug of remission of induction in APL.
Leukemia, Promyelocytic, Acute ; therapy ; drug therapy ; therapeutics

Adult ; China ; Humans ; Leukemia, Myeloid, Acute/therapy* ; Leukemia, Promyelocytic, Acute

Acute Disease ; Female ; Humans ; Leukemia/therapy* ; Leukemia, Myeloid, Acute/therapy* ; Pregnancy ; Pregnancy Complications, Neoplastic/therapy*

Humans ; Leukemia, Promyelocytic, Acute ; diagnosis ; therapy